Regulatory Framework for Cosmetic Products in South Korea
South Korean cosmetic products are among the most popular products in the beauty industry. But how are these products regulated? Safety is one of the major goals of South Korean cosmetics regulations and the country has been aligning its regulations with the European Union.


In South Korea, the Cosmetics Act represents the main legal regulatory framework for cosmetics. There are other regulations, standards and guidance documents that support this Act and which allow the country to have a comprehensive framework to manage this type of products. The Cosmetics Act provides standards for the manufacture, importing and sale of cosmetics and cosmetic ingredients, including detailed requirements for the labelling and advertising of products. The Ministry of Food and Drug Safety (MFDS) is the competent authority that enacts and executes cosmetic regulations in South Korea, including the register of functional products. The South Korean Pharmaceutical Traders Association (KPTA) is responsible for issuing importing cosmetic approvals and supervising cosmetic trading.

According to the Cosmetics Act, cosmetic products are defined as “products/articles intended to be applied to the human body by friction, spraying or other means, in order to cleanse it, beautify it, make it more attractive, improve its appearance, maintain or improve the state of health of the skin or hair, and which has surface effects“.

Cosmetics are divided into general cosmetics and functional cosmetics. Functional cosmetics are products that aid in functionally improving or changing the condition of skin and hair. Examples of functional cosmetics are: whitening products; anti-wrinkle products; sunscreens; hair dyes; epilating agent; acne products; etc.

General cosmetics are subject to a post-market surveillance and can be manufactured/imported without registration. On the other hand, functional cosmetics must undergo a complex registration process to obtain an approval letter from the MFDS before manufacturing or importing processes can be made. Additionally, importers of cosmetic products also have to obtain approval from the South Korean Pharmaceuticals Traders Association (KPTA).

A company must register for the type of cosmetic business that its products entails before conducting any commercial operations related to cosmetics. If a company wants to manufacture cosmetics, it must register itself as a “manufacturer”. But if it wants to import cosmetic products, it needs to be registered as a “marketing authorization holder” (MAH). When a company wishes to conduct activities associated with functional cosmetics, it needs to be registered as MAH. The MAH has several responsibilities: product registration, safety, quality, labelling, advertising, cosmetic claims, custom clearances, among other regulatory activities. A cosmetic supervisor (with specific qualifications and training) needs to be designated by the MAH and registered at MFDS.


Safe containers and packaging must be used with the intention of preventing children poisoning due to misuse. The information required to appear on the label depends on the category of the cosmetic and its volume, among other determinants. The product’s name, the name of the MAH, the expiry date and the lot number are mandatory to appear on the label of all products.

The MFDS lays down some strict requirements for claims made for functional cosmetics. For example, if a product is approved as an “anti-wrinkle”, it may make claims like “anti-wrinkle”, “fine lines” and such, but it can not claim “anti-aging”. “Whitening” claims can be made if a cosmetic gets approval as whitening product. If a product does not get approved as a functional “whitening” product, it may only make claims such as “lightening” or “brightening”.

Some ingredients have been already approved by the MFDS to be used in certain functional cosmetics (with limitations). This means that if a manufacturer or importer wants to make available on the market a functional cosmetic which contains only ingredients approved (for that specific type of functional cosmetic), he does not need to provide clinical and efficacy data. The approval of these products will take about 7 days (“submission procedure”). If, on the contrary, the manufacturer/importer wishes to use unapproved ingredients, he must submit clinical and efficacy data, identifying the active ingredients, when applying for approval from the MFDS. This “approval process” may take 4-6 months to be concluded.

After approval from MFDS (and KPTA for imported products) and according to the type of cosmetic product, it needs to be submitted to lab testing in an institution located in South Korean territory.


In July 2019, the MFDS implemented the Regulations on the Standards of Natural and Organic Cosmetic Products. This Regulation specified “organic” and “natural” definitions, permitted ingredients, manufacturing processes and requirements for the business entity. For example, natural raw materials concentration should exceed 95% in a natural cosmetic. Organic cosmetics, besides the 95% concentration in natural raw materials, have to contain over 10% organic ingredients.

In January 2021, South Korea has introduced a new certification mechanism, which inspects raw materials instead of the final products. The preparation required for documents is reduced and, consequently, the work of the industry gets easier.

Besides South Korean natural and organic certification, companies can choose to follow other standards/certifications, such as COSMOS (see our post about natural and organic cosmetics).


The MFDS has recently updated the cosmetics regulation. The addition of some product categories (e.g., beauty soap bars, hair removal wax) and the simplification of the registration process of some functional cosmetics (whitening, anti-wrinkle, hair loss and hair dye products that contain certain ingredients) are two examples of the changes introduced. Additionally, functional products can no longer make any claims on atopic skin, as the term ‘atopic’ now can only be used in the pharmaceutical product category.

Although both South Korean and European Union cosmetics regulation primarily aim the safety of consumers, they still have striking differences. For example, some cosmetic products in the EU do not meet the definition of cosmetic products in South Korea and vice-versa. As this country represents a popular emerging market for EU brands, new opportunities for manufacturers and importers arise . It is essential to be up-to-date and understand the South Korean cosmetic regulations before entering this highly competitive market.

Our company has a team of regulatory experts that can help you place cosmetic products in the South Korean market. Do not hesitate to contact us at


  1. Cosmetics Act 17250 (Apr 7, 2020). Ministry of Food and Drug Safety. South Korea. Available at:
  2. South Korea Cosmetic Regulation. Chemlinked. Aug 07, 2020. Available at:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »